Loading…
NGL Fine-Chem (NGLFINE)₹2,935+1.97%Pharmaceuticals
In the Jun 2026 quarter (consolidated), NGL Fine-Chem reported sales of ₹139 Cr, up 33.8% from Jun 2025, and net profit of ₹18.04 Cr, up 100.0% year on year. For the year to Mar 2026, sales were ₹500 Cr and net profit ₹48.08 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79.79 | 87.83 | 99.78 | 90.80 | 92.76 | 88.76 | 94.78 | 104 | 120 | 128 | 149 | 139 |
| Expenses | 65.90 | 73.91 | 83.85 | 80.91 | 81.91 | 83.83 | 88.78 | 92.77 | 103 | 105 | 128 | 116 |
| Operating Profit | 14.02 | 14.04 | 16.04 | 9.01 | 12.03 | 5.01 | 6.01 | 11.02 | 17.03 | 22.06 | 21.05 | 23.05 |
| OPM % | 16.9% | 15.9% | 15.9% | 10.0% | 12.0% | 6.0% | 7.0% | 10.9% | 13.9% | 17.9% | 13.9% | 16.9% |
| Other Income | 3.01 | 4.01 | 4.01 | 6.01 | 5.01 | 0.00 | −1.01 | 6.01 | 2.01 | 5.01 | 2.01 | 7.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Depreciation | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.98 | 4.98 | 4.98 | 4.98 | 4.98 |
| Profit before tax | 14.02 | 14.01 | 16.03 | 12.02 | 13.01 | 1.01 | 1.01 | 12.01 | 13.02 | 21.02 | 18.01 | 24.04 |
| Tax % | 25.0% | 30.1% | 23.0% | 22.0% | 26.1% | −1.0% | 49.0% | 22.0% | 26.0% | 24.0% | 24.1% | 25.1% |
| Net Profit | 10.03 | 10.02 | 12.03 | 9.02 | 10.02 | 1.01 | 1.01 | 9.02 | 10.03 | 16.04 | 13.02 | 18.04 |
| EPS (Rs) | 16.92 | 16.20 | 19.90 | 14.89 | 15.85 | 2.06 | 0.86 | 14.92 | 15.57 | 25.37 | 21.80 | 29.72 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 152 | 257 | 317 | 278 | 338 | 367 | 500 | 535 |
| Expenses | 121 | 130 | 178 | 248 | 242 | 285 | 332 | 420 | 451 |
| Operating Profit | 32.08 | 22.05 | 80.23 | 68.16 | 35.09 | 54.15 | 35.07 | 80.21 | 83.19 |
| OPM % | 21.0% | 13.9% | 30.9% | 20.9% | 12.9% | 15.9% | 10.0% | 15.9% | 15.6% |
| Other Income | 4.01 | 1.01 | 8.01 | 11.02 | 6.01 | 14.02 | 8.01 | 8.01 | 16.04 |
| Interest | 2.99 | 2.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.99 | 4.99 | 3.96 |
| Depreciation | 5.98 | 7.97 | 7.97 | 9.96 | 10.97 | 11.95 | 11.95 | 19.91 | 19.92 |
| Profit before tax | 28.03 | 12.01 | 78.13 | 67.11 | 27.04 | 54.09 | 28.03 | 63.04 | 76.09 |
| Tax % | 27.0% | 31.0% | 27.0% | 25.0% | 25.0% | 24.0% | 24.0% | 24.1% | — |
| Exceptional items | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −4.99 | — |
| Net Profit | 20.04 | 8.01 | 57.10 | 50.09 | 20.06 | 41.11 | 21.04 | 48.08 | 57.13 |
| EPS (Rs) | 32.53 | 13.47 | 91.70 | 80.56 | 33.11 | 66.75 | 34.12 | 77.78 | 92.46 |
| Dividend payout % | 5.0% | 13.0% | 2.0% | 2.0% | 5.0% | 3.0% | 5.0% | 2.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | 89.23 | 96.18 | 151 | 201 | 220 | 261 | 280 | 327 |
| Borrowings | 27.09 | 28.08 | 16.06 | 30.10 | 32.10 | 34.12 | 78.27 | 123 |
| Other Liabilities | 23.11 | 26.13 | 36.17 | 44.22 | 32.16 | 59.28 | 75.36 | 94.45 |
| Total Liabilities | 142 | 154 | 208 | 278 | 288 | 357 | 436 | 547 |
| Fixed Assets | 61.15 | 68.19 | 64.11 | 89.17 | 88.14 | 86.19 | 143 | 164 |
| CWIP | 0.00 | 0.00 | 12.04 | 6.02 | 26.11 | 46.16 | 50.15 | 95.41 |
| Investments | 9.01 | 11.02 | 29.04 | 29.05 | 39.05 | 54.06 | 60.07 | 39.06 |
| Other Assets | 73.28 | 75.19 | 102 | 154 | 134 | 172 | 184 | 248 |
| Inventories | 19.03 | 28.03 | 38.05 | 56.11 | 27.02 | 43.05 | 51.05 | 70.10 |
| Trade receivables | 33.05 | 26.01 | 38.05 | 64.07 | 66.11 | 90.12 | 83.06 | 131 |
| Cash & equivalents | 3.01 | 3.01 | 5.02 | 1.01 | 13.05 | 2.01 | 5.01 | 5.02 |
| Total Assets | 142 | 154 | 208 | 278 | 288 | 357 | 436 | 547 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 9.01 | 20.02 | 27.03 | 14.01 | 35.01 | 20.02 | 32.05 | 43.07 |
| Cash from investing activity | −9.97 | −19.93 | −24.92 | −13.96 | −26.92 | −26.91 | −69.76 | −70.77 |
| Cash from financing activity | 0.00 | −0.99 | −0.99 | −0.99 | −0.99 | −0.99 | 36.92 | 29.92 |
| Net cash flow | −1.01 | 0.00 | 2.01 | −1.01 | 7.02 | −7.01 | 0.00 | 2.01 |
| Capex | 13.99 | 14.99 | 16.99 | 55.96 | 30.98 | 28.99 | 73.97 | 90.03 |
| Free cash flow | −5.99 | 5.99 | 9.97 | −14.98 | 4.99 | −7.99 | −40.94 | −42.94 |
| CFO / OP % | 50.0% | 110.0% | 60.0% | 45.0% | 121.0% | 62.0% | 111.0% | 73.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 78 | 62 | 52 | 73 | 85 | 96 | 81 | 94 |
| Inventory days | 107 | 156 | 133 | 138 | 70 | 99 | 102 | 107 |
| Days payable | 91 | 115 | 102 | 90 | 62 | 111 | 102 | 96 |
| Cash conversion cycle | 92 | 101 | 81 | 119 | 92 | 82 | 80 | 103 |
| Working capital days | 69 | 57 | 68 | 89 | 67 | 75 | 49 | 59 |
| ROCE % | — | 14.1% | 54.0% | 34.0% | 12.0% | 20.0% | 10.0% | 19.0% |
For the Jun 2026 quarter, NGL Fine-Chem reported sales of ₹139 Cr, up 33.8% year on year and net profit of ₹18.04 Cr, up 100.0% year on year. The operating margin was 16.9%.
NGL Fine-Chem's sales for the year to Mar 2026 were ₹500 Cr; over the last twelve months they were ₹535 Cr.
Net profit for the year to Mar 2026 was ₹48.08 Cr, and ₹57.13 Cr over the last twelve months. Earnings per share over the same trailing period were ₹92.46.
NGL Fine-Chem reported borrowings of ₹123 Cr at Mar 2026, against cash and equivalents of ₹5.02 Cr.
Cash from operations was ₹43.07 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹42.94 Cr.